<p>新世界顧問公司在最近向美國證券交易委員會（SEC）披露的信息中表示，在第二季度將其在強生（NYSE:JNJ - 免費報告）股票中的持倉增加了 61.4%。該基金在季度內購買了 1,347 股後，持有該公司 3,541 股股票。截至其最近向 SEC 提交的文件，新世界顧問公司在強生的持股價值為 541,000 美元。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<ul>
<li>為什麼 GRAIL 股票可能是生物科技的下一個重大突破</li>
</ul>
<p>其他幾家機構投資者和對沖基金也對該公司的持倉進行了調整。先鋒集團在第二季度將其在強生的股份增加了 1.3%。先鋒集團目前擁有 237,047,859 股該公司的股票，價值 36,209,060,000 美元，在上個季度又購買了 3,085,180 股。Geode Capital Management LLC 在第二季度將其在強生的持股增加了 2.1%。Geode Capital Management LLC 目前擁有 60,609,476 股該公司的股票，價值 9,227,988,000 美元，在此期間又收購了 1,225,676 股。北方信託公司在第一季度將其在強生的持倉提高了 0.4%。北方信託公司目前擁有 30,943,820 股該公司的股票，價值 5,131,723,000 美元，在上個季度又購買了 130,645 股。紐約梅隆銀行在第二季度將其在強生的股份增加了 2.7%。紐約梅隆銀行目前擁有 23,802,503 股該公司的股票，價值 3,635,832,000 美元，在此期間又購買了 620,039 股。最後，法律與一般集團在第二季度將其在強生的持倉增加了 6.2%。法律與一般集團目前擁有 18,917,274 股該公司的股票，價值 2,889,614,000 美元，在上個季度又購買了 1,097,855 股。69.55% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>強生股票表現</h2>
<p>強生（NYSE:JNJ）週五開盤價為 203.88 美元。該公司的 50 日簡單移動平均線為 188.25 美元，200 日簡單移動平均線為 171.55 美元。公司流動比率為 0.80，當前比率為 1.07，債務與股本比率為 0.50。該股票的市值為 4912.1 億美元，市盈率為 19.68，市盈率增長比率為 2.19，貝塔值為 0.38。強生的 52 周低點為 140.68 美元，52 周高點為 206.94 美元。</p>
<ul>
<li>3 只適合不安市場的防禦性股票</li>
</ul>
<p>強生（NYSE:JNJ - 獲取免費報告）最近於 8 月 30 日發佈了季度財報。公司報告本季度每股收益為 2.26 美元。該公司本季度的收入為 240.2 億美元。強生的淨利潤率為 27.26%，股本回報率為 32.73%。分析師預計強生在當前財政年度的每股收益將達到 10.58 美元。</p>
<h2>強生宣佈分紅</h2>
<p>該公司還最近披露了一項季度分紅，將於 12 月 9 日支付。11 月 25 日的登記投資者將獲得 1.30 美元的分紅。這相當於年化 5.20 美元的分紅，收益率為 2.6%。該分紅的除息日為 11 月 25 日。強生的分紅支付比率目前為 50.19%。</p>
<h2>內部人士下注</h2>
<ul>
<li>持有評級，高回報？3 只可能超出預期的股票</li>
</ul>
<p>在其他強生新聞中，執行副總裁 Jennifer L. Taubert 於 9 月 4 日星期四出售了 56,471 股強生股票。股票以 177.81 美元的平均價格出售，總交易額為 10,041,108.51 美元。交易完成後，該執行副總裁在公司持有 178,013 股，價值約 31,652,491.53 美元。此次交易使其持股減少了 24.08%。該交易已在 SEC 的法律文件中披露，可以通過此鏈接訪問。公司內部人士持有該公司 0.16% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些股票研究分析師最近對該股票發表了評論。花旗集團將強生股票的目標價格從 213.00 美元上調至 215.00 美元，並在 10 月 15 日的報告中給予公司 “買入” 評級。高盛集團將強生的目標價格從 186.00 美元上調至 212.00 美元，並在 10 月 9 日的研究報告中給予公司 “買入” 評級。加拿大豐業銀行在 11 月 13 日的研究報告中開始覆蓋強生，給予 “行業表現優於大盤” 評級，並設定 230.00 美元的目標價格。大和資本市場在 10 月 20 日的研究報告中將強生的評級從 “中性” 上調至 “表現優於大盤”，並設定 203.00 美元的目標價格。最後，富國銀行在 10 月 3 日的報告中設定強生的目標價格為 212.00 美元，並給予該股票 “超配” 評級。四位投資分析師給予該股票 “強烈買入” 評級，十三位給予 “買入” 評級，九位給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為 201.05 美元。</p>
<p><strong>查看我們關於 JNJ 的最新報告</strong></p>
<h2>強生簡介</h2>
<p>（免費報告）</p>
<p>強生是一家控股公司，專注於醫療領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過強生</li>
<li>什麼樣的股票是好的分紅股票？</li>
<li>MarketBeat 週報 – 11/17 - 11/21</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>一項宏偉的人工智能投資？斯坦利·德魯肯米勒的最新科技動態</li>
<li>股票交易術語 - 每位投資者都需要了解的股票術語</li>
<li>12 位分析師剛剛上調了 CrowdStrike 的目標價——他們預見了什麼</li>
</ul>
<p><strong>想看看其他對強生持有股份的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取強生（NYSE:JNJ - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>新世界顧問公司（New World Advisors LLC）在第二季度將其在強生（Johnson & Johnson）的持股增加了 61.4%，目前持有 3,541 股，價值 54.1 萬美元。其他機構投資者如先鋒集團（Vanguard）、Geode Capital 和法律與一般保險公司（Legal & General）也調整了他們的持倉。強生的股票開盤價為 203.88 美元，市值為 4912.1 億美元。該公司宣佈季度股息為 1.30 美元，將於 12 月 9 日支付</p>

<p>New World Advisors LLC grew its position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 61.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,541 shares of the company's stock after purchasing an additional 1,347 shares during the quarter. New World Advisors LLC's holdings in Johnson &amp; Johnson were worth $541,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>新世界顧問公司在最近向美國證券交易委員會（SEC）披露的信息中表示，在第二季度將其在強生（NYSE:JNJ - 免費報告）股票中的持倉增加了 61.4%。該基金在季度內購買了 1,347 股後，持有該公司 3,541 股股票。截至其最近向 SEC 提交的文件，新世界顧問公司在強生的持股價值為 541,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 GRAIL 股票可能是生物科技的下一個重大突破</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Johnson &amp; Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Johnson &amp; Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company's stock valued at $9,227,988,000 after acquiring an additional 1,225,676 shares during the period. Northern Trust Corp raised its position in Johnson &amp; Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock valued at $5,131,723,000 after purchasing an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Johnson &amp; Johnson by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company's stock worth $3,635,832,000 after purchasing an additional 620,039 shares during the period. Finally, Legal &amp; General Group Plc grew its position in Johnson &amp; Johnson by 6.2% during the 2nd quarter. Legal &amp; General Group Plc now owns 18,917,274 shares of the company's stock worth $2,889,614,000 after purchasing an additional 1,097,855 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金也對該公司的持倉進行了調整。先鋒集團在第二季度將其在強生的股份增加了 1.3%。先鋒集團目前擁有 237,047,859 股該公司的股票，價值 36,209,060,000 美元，在上個季度又購買了 3,085,180 股。Geode Capital Management LLC 在第二季度將其在強生的持股增加了 2.1%。Geode Capital Management LLC 目前擁有 60,609,476 股該公司的股票，價值 9,227,988,000 美元，在此期間又收購了 1,225,676 股。北方信託公司在第一季度將其在強生的持倉提高了 0.4%。北方信託公司目前擁有 30,943,820 股該公司的股票，價值 5,131,723,000 美元，在上個季度又購買了 130,645 股。紐約梅隆銀行在第二季度將其在強生的股份增加了 2.7%。紐約梅隆銀行目前擁有 23,802,503 股該公司的股票，價值 3,635,832,000 美元，在此期間又購買了 620,039 股。最後，法律與一般集團在第二季度將其在強生的持倉增加了 6.2%。法律與一般集團目前擁有 18,917,274 股該公司的股票，價值 2,889,614,000 美元，在上個季度又購買了 1,097,855 股。69.55% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>強生股票表現</h2>
</div><p>NYSE:JNJ opened at $203.88 on Friday. The firm's fifty day simple moving average is $188.25 and its 200-day simple moving average is $171.55. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson &amp; Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $206.94.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ）週五開盤價為 203.88 美元。該公司的 50 日簡單移動平均線為 188.25 美元，200 日簡單移動平均線為 171.55 美元。公司流動比率為 0.80，當前比率為 1.07，債務與股本比率為 0.50。該股票的市值為 4912.1 億美元，市盈率為 19.68，市盈率增長比率為 2.19，貝塔值為 0.38。強生的 52 周低點為 140.68 美元，52 周高點為 206.94 美元。</p>
</div><ul>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只適合不安市場的防禦性股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts expect that Johnson &amp; Johnson will post 10.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近於 8 月 30 日發佈了季度財報。公司報告本季度每股收益為 2.26 美元。該公司本季度的收入為 240.2 億美元。強生的淨利潤率為 27.26%，股本回報率為 32.73%。分析師預計強生在當前財政年度的每股收益將達到 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>強生宣佈分紅</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio is presently 50.19%.</p>
<div class="lb-trans"><p>該公司還最近披露了一項季度分紅，將於 12 月 9 日支付。11 月 25 日的登記投資者將獲得 1.30 美元的分紅。這相當於年化 5.20 美元的分紅，收益率為 2.6%。該分紅的除息日為 11 月 25 日。強生的分紅支付比率目前為 50.19%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li>
</ul>
<div class="lb-trans"><ul>
<li>持有評級，高回報？3 只可能超出預期的股票</li>
</ul>
</div><p>In other Johnson &amp; Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson &amp; Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他強生新聞中，執行副總裁 Jennifer L. Taubert 於 9 月 4 日星期四出售了 56,471 股強生股票。股票以 177.81 美元的平均價格出售，總交易額為 10,041,108.51 美元。交易完成後，該執行副總裁在公司持有 178,013 股，價值約 31,652,491.53 美元。此次交易使其持股減少了 24.08%。該交易已在 SEC 的法律文件中披露，可以通過此鏈接訪問。公司內部人士持有該公司 0.16% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities research analysts have recently commented on the stock. Citigroup upped their target price on shares of Johnson &amp; Johnson from $213.00 to $215.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, October 15th. The Goldman Sachs Group upped their price objective on Johnson &amp; Johnson from $186.00 to $212.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, October 9th. Scotiabank started coverage on Johnson &amp; Johnson in a research note on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $230.00 target price on the stock. Daiwa Capital Markets upgraded Johnson &amp; Johnson from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $203.00 price target for the company in a research note on Monday, October 20th. Finally, Wells Fargo &amp; Company set a $212.00 price target on Johnson &amp; Johnson and gave the stock an &#34;overweight&#34; rating in a report on Friday, October 3rd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $201.05.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對該股票發表了評論。花旗集團將強生股票的目標價格從 213.00 美元上調至 215.00 美元，並在 10 月 15 日的報告中給予公司 “買入” 評級。高盛集團將強生的目標價格從 186.00 美元上調至 212.00 美元，並在 10 月 9 日的研究報告中給予公司 “買入” 評級。加拿大豐業銀行在 11 月 13 日的研究報告中開始覆蓋強生，給予 “行業表現優於大盤” 評級，並設定 230.00 美元的目標價格。大和資本市場在 10 月 20 日的研究報告中將強生的評級從 “中性” 上調至 “表現優於大盤”，並設定 203.00 美元的目標價格。最後，富國銀行在 10 月 3 日的報告中設定強生的目標價格為 212.00 美元，並給予該股票 “超配” 評級。四位投資分析師給予該股票 “強烈買入” 評級，十三位給予 “買入” 評級，九位給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，共識目標價格為 201.05 美元。</p>
</div><p><strong>Check Out Our Latest Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 JNJ 的最新報告</strong></p>
</div><h2>Johnson &amp; Johnson Profile</h2>
<div class="lb-trans"><h2>強生簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>強生是一家控股公司，專注於醫療領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>MarketBeat Week in Review – 11/17 - 11/21</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過強生</li>
<li>什麼樣的股票是好的分紅股票？</li>
<li>MarketBeat 週報 – 11/17 - 11/21</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>一項宏偉的人工智能投資？斯坦利·德魯肯米勒的最新科技動態</li>
<li>股票交易術語 - 每位投資者都需要了解的股票術語</li>
<li>12 位分析師剛剛上調了 CrowdStrike 的目標價——他們預見了什麼</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對強生持有股份的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取強生（NYSE:JNJ - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

New World Advisors LLC 增加了其在強生公司 $JNJ 的股票持倉